홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

(-)-Salbutamol

HCID 123600
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
34391-04-3
표준 SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1
InChIKey
NDAUXUAQIAJITI-LBPRGKRZSA-N
분자식
C13H21NO3
평균 분자량
239.31 g/mol
단동위원소 질량
239.15214353

개요

(R)-salbutamol is an albuterol.

이름 및 식별자

우선 이름
(-)-Salbutamol
IUPAC
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
영어명
Levalbuterol
분자식
C13H21NO3
분자량
239.31

이름 및 동의어

LevalbuterolLevosalbutamol(-)-Salbutamol34391-04-3(R)-salbutamol(-)-AlbuterolR-Salbutamol4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolEDN2NBH5SSASF-1096CHEBI:8746DTXSID80187964
이름 더 보기
LEVALBUTEROL HCLSalbutamolr-albuterolLevalbutreol(L)-ALBUTEROLR-SALBUTAMOL HCLLEVOSALBUTEROLHCL
levosalbutamolum4-((1R)-2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenolAlbuterol (r)-Levalbuterol InhalationRefChem:56698Hydrochloride, LevalbuterolHydrochloride, LevosalbutamolDTXCID40110455

데이터베이스 식별자

CAS
34391-04-3
PubChem CID
123600
DTXSID
DTXSID80187964
ChEMBL
CHEMBL1002
ChEBI
CHEBI:8746
UNII
EDN2NBH5SS
EC Number
608-983-3
Nikkaji
J428.072E

물성

구조 계산 물성

XLogP
0.3
극성 표면적
72.7 Ų
수소 결합 공여자 수
4
수소 결합 수용자 수
4
회전 가능 결합 수
5
무거운 원자 수
17
형식 전하
0
복잡도
227

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists
Collision Cross Section153.47 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

끓는 점
433.5 · 433.5±40.0 °C(Predicted)
밀도
1.152 · 1.152±0.06 g/cm3(Predicted)
산도 계수 (pKa)
9.99 · 9.99±0.31(Predicted)
InChI
InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/s3
InChIKey
NDAUXUAQIAJITI-PLAQIDKDNA-N
SMILES
C1(=CC=C(O)C(CO)=C1)[C@@H](O)CNC(C)(C)C |&1:9,r|

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Exposure RoutesSystemic absorption is rapid following aerosol administration.
Toxicity Summary · 1건

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub>=1100 mg/kg (orally in mice)

안전 데이터

HS 번호
2922509090
risk_code
22
hazard_code
Xn
safety_code
36

화학 및 산업

약리 정보

Protein Bindingplasma protein binding is relatively low.
PharmacodynamicsIt acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.
Mechanism of Action · 1건

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Biological Half-Life3.3 - 4 hours
Metabolism/Metabolites · 2건

Pure (R)-salbutamol formulation known as levosalbutamol is metabolised up to 12 times faster than (S)-salbutamol by intestine.

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours

FDA Pharmacological Classification · 6건

EDN2NBH5SS

LEVALBUTEROL

Mechanisms of Action [MoA] - Adrenergic beta2-Agonists

Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist

Levalbuterol is a beta2-Adrenergic Agonist. The mechanism of action of levalbuterol is as an Adrenergic beta2-Agonist.

LEVALBUTEROL

Absorption, Distribution and Excretion · 2건

Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications.

관련 반응

3건
반응 기록 만들기
HRID 1455720 반응식
HRID 1455720생성물로
HRID 2375770 반응식
HRID 2375770생성물로
HRID 2375771 반응식
HRID 2375771생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

excreted into the urine.

용도 및 제조

UsesFor symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.
응용 분야 · 2건

개요Levalbuterol was launched in the US for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. It is the single R-enantiomer version of racemic albuterol (salbutamol) marketed for more than 30 years as a mainstay in the treatment of asthma. The R-isomer can be obtained with an excellent optical purity by enantiomeric purification based on the separation of diastereomeric tartrates. This isomer retains solely the desired bronchodilating effect of the racemic mixture due to a potent agonistic effect on β2-adrenoceptors, with a lower incidence of β- mediated side effects such as pulse rate increase, tremor and decrease in blood glucose and potassium levels. A pivotal clinical trial with two doses of levalbuterol and racemic albuterol, given by nebulization, demonstrated a greater improvement in lung function for the pure enantiomer levalbuterol.

용도(R)-Salbutamol is used in composition and methods to reduce beta-agonist-mediated tachyphylaxis.

상·하류 제품 정보

상류 원료

Methyl 5-acetylsalicylate디메틸설파이드보란Palladium hydroxide3차-뷰틸아민브롬화수소